Product Information
GEMCITABINE HCL 1 GRAM VIAL is a generic product labeled by Sagent Pharmaceuticals, priced at $19.9960 per EA under NDC 25021023550. Its NADAC has been published 69 times since Oct 23, 2024.
FDA first approved this application on May 7, 2013. Its Orange Book therapeutic-equivalence code is AP.
Strength
1 g/25mL
Manufacturer
Sagent PharmaceuticalsNDC
25021023550
Classification
Generic
Dosage Form
INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
Route
INTRAVENOUS
Effective Date
2/19/2025
Active Ingredients
GEMCITABINE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA202485FDA Approved
5/7/2013
TE Code
AP
On Market Since
12/29/2014
Pharmacological Classes
Price Statistics
The NADAC for GEMCITABINE HCL 1 GRAM VIAL has been published 69 times since Oct 23, 2024, and over the history we have for it it has declined 5.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $19.9960 per EA |
|---|---|
| All-time high | $21.2267 (Dec 11, 2024) |
| All-time low | $19.9960 (Feb 19, 2025) |
| 52-week high | $19.9960 |
| 52-week low | $19.9960 |
| Median price | $19.9960 |
| Average price | $20.2338 |
| Largest weekly change | -3.0% (Feb 19, 2025) |
| Weeks tracked | 69 |
| Tracking since | Oct 23, 2024 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
0.0%
3Y
N/A
5Y
N/A
All
-5.8%
Last surveyed Feb 11, 2026 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the gemcitabine hydrochloride market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Sagent Pharmaceuticals manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
gemcitabine hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Nucleoside Metabolic Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of GEMCITABINE HCL 1 GRAM VIAL?
The current National Average Drug Acquisition Cost (NADAC) for GEMCITABINE HCL 1 GRAM VIAL, manufactured by Sagent Pharmaceuticals, is $19.9960 per EA (NDC 25021023550), effective Feb 11, 2026.
How has the price of GEMCITABINE HCL 1 GRAM VIAL changed over time?
Over the history we have for it, the NADAC for GEMCITABINE HCL 1 GRAM VIAL has declined 5.8%. It has been tracked across 69 weekly CMS publications since Oct 23, 2024.
What are the highest and lowest recorded NADAC prices for GEMCITABINE HCL 1 GRAM VIAL?
Since Oct 23, 2024, the NADAC for GEMCITABINE HCL 1 GRAM VIAL has ranged from a low of $19.9960 (Feb 19, 2025) to a high of $21.2267 (Dec 11, 2024), with a median of $19.9960 per EA.
Are there cheaper alternatives to GEMCITABINE HCL 1 GRAM VIAL?
No other NADAC-published product currently shares the active ingredient and strength of GEMCITABINE HCL 1 GRAM VIAL in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures GEMCITABINE HCL 1 GRAM VIAL?
GEMCITABINE HCL 1 GRAM VIAL (NDC 25021023550) is labeled by Sagent Pharmaceuticals, and CMS classifies it as a generic product.